↓ Skip to main content

Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis

Overview of attention for article published in Frontiers in oncology, January 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis
Published in
Frontiers in oncology, January 2022
DOI 10.3389/fonc.2021.780191
Pubmed ID
Authors

Selma Olsson Åkefeldt, Mohamad Bachar Ismail, Alexandre Belot, Giulia Salvatore, Nathalie Bissay, Désirée Gavhed, Maurizio Aricò, Jan-Inge Henter, Hélène Valentin, Christine Delprat

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 25%
Student > Doctoral Student 1 13%
Other 1 13%
Student > Master 1 13%
Student > Ph. D. Student 1 13%
Other 0 0%
Unknown 2 25%
Readers by discipline Count As %
Medicine and Dentistry 3 38%
Immunology and Microbiology 2 25%
Unknown 3 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2022.
All research outputs
#16,795,718
of 25,478,886 outputs
Outputs from Frontiers in oncology
#6,658
of 22,568 outputs
Outputs of similar age
#288,786
of 517,135 outputs
Outputs of similar age from Frontiers in oncology
#399
of 1,415 outputs
Altmetric has tracked 25,478,886 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,568 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 517,135 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,415 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.